ClinicalTrials.gg
RecruitingNCT07519135Updated Apr 23, 2026

A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

A Phase 1 interventional study of PF-08653944 in Healthy, sponsored by Pfizer. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Study summary

This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose.

The study includes adults with normal liver function and adults who have mild, moderate, or severe liver problems. By comparing these groups, researchers want to understand whether liver function changes how the medicine behaves in the body.

People who join the study will receive one injection of the study medicine. They will stay at the study clinic for a short time and return for follow-up visits so doctors can do blood tests, physical exams, and safety checks.

This study is not expected to provide direct medical benefit to participants. The information collected will help researchers develop future treatments and understand how this medicine may be used safely in people with liver disease.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age, male or female.
  • ≥21 kg/m² and body weight >50 kg at screening.
  • Group 1 (without hepatic impairment):

    • No known or suspected hepatic impairment.
    • Normal liver function tests (, AST, , albumin, PT within normal limits, with protocol-specified exceptions such as Gilbert's syndrome).
  • Groups 2-4 (with hepatic impairment):

    • Stable hepatic impairment classified as Class A (mild), B (moderate), or C (severe).
    • No worsening of hepatic status within 28 days prior to screening.
  • Women of must not be pregnant or breastfeeding and must agree to use highly effective .

Exclusion criteria

Exclusion Criteria:

  • medical or psychiatric conditions, including recent or active suicidal ideation or behavior.
  • Use of GLP-1 receptor agonists within 90 days (or 5 half-lives) prior to dosing.
  • Participation in another study or receipt of an investigational product within 30 days (or 5 half-lives) prior to dosing.
  • For hepatic-impairment groups only:

    • Hepatic carcinoma, hepatorenal syndrome, or limited .
    • Clinically active Grade 3 or 4 hepatic encephalopathy.
    • Severe uncontrolled ascites, recent gastrointestinal bleeding, or history of solid organ transplant.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants without Hepatic Impairment (HI) will receive a single dose of PF-08653944, administered as Subcutaneous (SC) injection.

    Drug: PF-08653944

  • Experimental
    Group 2

    Participants with mild HI will receive a single dose of PF-08653944, administered as SC injection.

    Drug: PF-08653944

  • Experimental
    Group 3

    Participants with moderate HI will receive a single dose of PF-08653944, administered as SC injection.

    Drug: PF-08653944

  • Experimental
    Group 4

    Participants with severe HI will receive a single dose of PF 08653944, administered as SC injection.

    Drug: PF-08653944

Interventions

  • Solution for injection

    Also known as: MET097

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum observed plasma concentration (Cmax) of PF-08653944

    Time frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

  2. PK: Area under the plasma concentration (AUC) of PF-08653944

    Time frame: Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: First dose through study completion, approximately 11 Weeks after last dose of study intervention.

07

Study locations

3 of 3 sites recruiting
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
  • Genesis Clinical Research
    Tampa, Florida 33603, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Jul 9, 2027
CompletionEst.
Jul 9, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519135
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 15, 2026
Primary completion
Jul 9, 2027 (estimated)
Completion
Jul 9, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion